Nonhuman primate (NHP) models may contribute to advance research in Alzheimer’s disease (AD) thanks to their genetic, anatomical and physiological similarities with humans. However, their use in AD research is limited by significant challenges, including long generation times, ethical considerations and technical challenges of genetic modification.
Researchers from the University of Queensland and affiliated organizations recently presented preclinical data for the novel C3a receptor (C3aR) antagonist JR-14a, being developed as a neuroprotective agent for the treatment of post-stroke neuroinflammation.
The main causes of vascular cognitive impairment and dementia (VCID) are the breakdown of the blood-brain barrier, reactive astrogliosis and loss of myelination, but its molecular and cellular mechanisms are not clear enough.
The discovery of a complex formed by two types of ion channels in neurons has allowed researchers from Heidelberg University to develop an inhibitor that stopped motor neuron degeneration in amyotrophic lateral sclerosis (ALS) in mouse models and human brain organoids.
A Biogen Inc. patent describes new non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia, inflammatory disorders and autoimmune diseases.
Myrobalan Therapeutics Inc. has been awarded a $400,000 grant from the ALS Association to support the advancement of its colony-stimulating factor 1 receptor (CSF-1R) inhibitor for the treatment of amyotrophic lateral sclerosis (ALS).
Vandria SA has been awarded two grants totaling €3.8M (US$4.1M) from Innosuisse and Eurostars to support its two lead drug candidates addressing CNS and muscle diseases, respectively.
Stroke is the main neurologic cause of global morbidity and mortality with a global prevalence of more than 100 million last year. Under neuropathological conditions such as excitotoxicity associated with stroke, the pro-glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) enhances glucose consumption which leads to redox stress and apoptotic neuronal death.
Cantabio Pharmaceuticals Inc. has been awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of a cell-penetrant DJ-1 protein replacement therapeutic candidate for the treatment of Parkinson’s disease.
RSS
